ArticleNeurology and therapy2026

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Piero Barbanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.